Nachrichten zur Fate Therapeutics Inc. Aktie

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Starbucks, Sage, Outset Medical, and Super Micro and Encourages Investors to Contact the Firm

NEW YORK, Sept. 14, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE

NEW YORK, Sept. 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Starbucks, Sage, Outset Medical, and Super Micro and Encourages Investors to Contact the Firm

NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Shareholders that lost money on Sage Therapeutics, Inc. (SAGE) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

SAGE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

SAN DIEGO, Sept. 07, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP…

SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline

SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline…

SAGE INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP…

ROSEN, NATIONAL TRIAL COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE

NEW YORK, Sept. 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

SAGE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sage Therapeutics, Inc. and Encourages Investors to Contact the Firm

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law…

RAPT Therapeutics Reports Second Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE

NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Sage Therapeutics, Inc., (SAGE) Q2 2024 Earnings Call Transcript

…

Fate Therapeutics announces resignation of CFO Edward Dulac

…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors Sage Therapeutics, Inc. – SAGE

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Earnings call: Fate Therapeutics reports on clinical progress and finances By Investing.com

Earnings call: Fate Therapeutics reports on clinical progress and finances…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE

NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript

…

Sage Therapeutics, Inc. (SAGE) Q1 2024 Earnings Call Transcript

…

Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress

Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.…

Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics

HUNTSVILLE, Ala., March 26, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company developing…

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company…

Fate Therapeutics prices stock offering at $5.50 per share By Investing.com

Fate Therapeutics prices stock offering at $5.50 per share…

RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm

NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript

…

Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y

Fate Therapeutics (FATE) reports encouraging fourth-quarter results as loss narrows year over year due to lower operating expenses.…

RAPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Investors of RAPT Therapeutics, Inc. (NASDAQ: RAPT)

RADNOR, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

NEW YORK, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a…

SAGE Therapeutics, Inc. (SAGE) Q4 2023 Earnings Call Transcript

…

Sage Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation

…

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated…

Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Call Transcript

…

SAGE Therapeutics, Inc. (SAGE) Q3 2023 Earnings Call Transcript

…

Sage Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

SHAREHOLDER ALERT: Morris Kandinov Investigating ARDX, LESL, ENVX, and FATE; Shareholders are Encouraged to Contact the Firm

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of…

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a…

COMPASS Pathways appoints Daphne Karydas to its Board of Directors

LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to…

Lifshitz Law PLLC Announces Investigations of Sotera Health Co. (NASDAQ: SHC), Fate Therapeutics, Inc. (NASDAQ: FATE), National Vision Holdings, Inc. (NASDAQ: EYE)

NEW YORK, Sept. 09, 2023 (GLOBE NEWSWIRE) -- Sotera Health Co. (NASDAQ: SHC)…

dpa-AFX ProFeed